Abstract:Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments. Targeted therapy and immunotherapy with checkpoint inhibitors have changed the history of this disease. To date, more than half of advanced melanoma patients are alive at 5 years; despite this breakthrough, approximately half of the patients still do not respond to treatment. For these reasons, new therapeutic strategies are required to expand the number of patients who can benefit from immunotherapy or combination with targeted therapy. Current research aims at preventing primary and acquired resistance, which are both responsible for treatment failure in about 50% of patients. This could increase the effectiveness of available drugs and allow for the evaluation of new combinations and new targets. The main pathways and molecules under study are the IDO inhibitor, TLR9 agonist, STING, LAG-3, TIM-3, HDAC inhibitors, pegylated IL-2 (NKTR-214), GITR, and adenosine pathway inhibitors, among others (there are currently about 3000 trials that are evaluating immunotherapeutic combinations in different tumors). Other promising strategies are cancer vaccines and oncolytic viruses. Another approach is to isolate and remove immune cells (DCs, T cells, and NK cells) from the patient's blood or tumor infiltrates, add specific gene fragments, expand them in culture with growth factors, and re-inoculate into the same patient. TILs, TCR gene transfer, and CAR-T therapy follow this approach. In this article, we give an overview over the current status of melanoma therapies, the clinical rationale for choosing treatments, and the new immunotherapy approaches.

Research Advances in the Treatment of Melanoma by Treat Melanoma.

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Non-Surgical Treatment Methodologies and Prevention for Malignant Melanoma

Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances

Immunotherapy and delivery systems for melanoma

Advances in treatment of melanoma with immunotherapy

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes

Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle Vaccines

Progress of targeted therapy and immunotherapy for advanced melanoma

Targeted therapeutic strategies for melanoma

Recent Advances in Nanotechnology for the Treatment of Melanoma

Peptide nanovaccine in melanoma immunotherapy

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Advancements in Melanoma Therapies: From Surgery to Immunotherapy

Advances in Cancer Vaccine Research

Multifunctional Nanoparticle Approach for Targeting Melanoma

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Melanoma Management: From Epidemiology to Treatment and Latest Advances

Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects

Immunotherapy of melanoma: a critical review of current concepts and future strategies.